

## When critical intellectual property is stolen, identify the leak source

Average pharmaceutical leaks can cost millions of dollars, harm competitive position, and challenge critical partnerships. EchoMark provides definitive leak attribution in minutes, even from a printed photo of a report.

EchoMark embeds invisible, individualized watermarks into every clinical summary, regulatory filing, and trial protocol – so when your research data surfaces at a competitor, you have forensic evidence of who leaked it.

### LEAKED CONTENT

**CONFIDENTIAL - FOR REGULATORY SUBMISSION USE ONLY**

**VERIXA BIOPHARMACEUTICALS, INC.**  
Clinical Development - Regulatory Affairs Division  
**PHASE III CLINICAL TRIAL SUMMARY REPORT**  
IND 114-947 | PROTOCOL VX-2047-P3-001 | FDA REG SUBMISSION PACKAGE  
Page 1 of 28  
Version: 1.1 FINAL  
Date: Feb 28, 2025

Compound: VX-2047 (vexinapril sodium)  
Indication: Treatment-resistant hypertension with renal complication  
Study Phase: Phase III, Randomized, Double-Blind, Placebo-Controlled  
Sites: 42 investigational sites across 8 countries  
Patients Enrolled: 1,847 (ITT Population: 1,802)  
Primary Endpoint:  $\sqrt{RBP} - p < 0.0001$   
Submission Target: Q3 2024 (FDA Filing)

**DISTRIBUTION RESTRICTION:** This document contains commercially sensitive unpublished clinical data. Distribution is restricted to named regulatory affairs personnel and designated FDA reviewers. Unauthorized disclosure may compromise patent exclusivity and regulatory standing.

**EXECUTIVE SUMMARY**  
VX-2047 demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure compared to placebo in patients with treatment-resistant hypertension over 52 weeks of therapy. The compound achieved its pre-specified primary endpoint and all key secondary endpoints.

| Endpoint                                 | VX-2047 (n=901) | Placebo (n=901) | $\Delta$ (95% CI) | p-value |
|------------------------------------------|-----------------|-----------------|-------------------|---------|
| RBP reduction (mmHg) at 52wk             | -24.8           | -8.3            | -16.5             | <0.0001 |
| RBP reduction (mmHg) at 12wk             | -14.2           | -4.9            | -9.3              | <0.0001 |
| BP goal attainment (<130/80)             | 61.4%           | 28.7%           | 32.7%             | <0.0001 |
| eGFR change (mL/min/1.73m <sup>2</sup> ) | +2.1            | -3.4            | 5.5               | 0.0002  |
| SACE composite (% patients)              | 4.2%            | 7.8%            | -3.6%             | 0.0001  |

**Urgent: Phase 3 AE Data Summary - Pre-FDA Review**

...We have finalized the clean dataset for (Drug Code: VX-880-B). As feared, the primary endpoint, was not met in cohorts C and D. Crucially, the occurrence of Severe Adverse Reactions (SARs) is 30% higher than the Phase 2 projections. We are analyzing the correlation now.

Dr. Vance suggests a 3-month delay on the FDA pre-IND package submission.

Do NOT distribute this externally. We are in a closed period.

### LEAK IDENTIFICATION

**Sample: Leaked PDF**

**Exact Match**

**john.smith@echomark.com**  
Based on Digital Stamp Detector, Invisible Watermark Detector

**Digital Stamp Detector**

Chance of error  
0%

Based on identification of the unguessable key embedded within the content of this marked copy.

**Result**  
john.smith@echomark.com

**Invisible Watermark Detector**

Chance of error  
<0.0001%

Based on the number of matching marks and the detector precision.

**Result**  
john.smith@echomark.com

### HOW IT WORKS

01

#### Watermark

EchoMark silently embeds invisible watermarks into every email, document, image, and screen



02

#### Leak occurs

A screenshot, photo, printout, or forwarded file appears outside your organization



03

#### Upload artifact

Submit the leaked artifact into EchoMark's investigation tool



04

#### Definitive answer

Identify whose copy was leaked, with a confidence score and chain of custody

### RECENT LEAKS

#### US DEPARTMENT OF JUSTICE

Miami healthcare provider employee used phone to take photos of confidential patient profiles

#### HIPAA JOURNAL

Former Nuance employee sentenced for 1.2 Million-record Geisinger Health System data breach

#### FIERCE PHARMA

J&J files trade secret lawsuit against former oncology employee linked to Summit Therapeutics

#### Contact Us

General Inquiries: [info@echomark.com](mailto:info@echomark.com)  
Jeff Bednarczyk, Account Director: [jeff@echomark.com](mailto:jeff@echomark.com)  
Zak Lewis, Account Director: [zak@echomark.com](mailto:zak@echomark.com)

Schedule  
a Demo



Product  
Videos



## WHAT WE PROTECT

### Protection surfaces

- ✓ Email body & attached documents
- ✓ PDFs and images
- ✓ Secure file sharing via link (SecureView)
- ✓ Plaintext and HTML content
- ✓ Screens

### Leak types we can trace

- 💧 Phone photos of screens or printouts
- 💧 Screenshots
- 💧 Printed and photocopied documents
- 💧 Copy-pasted or retyped text
- 💧 Forwarded files and re-shared links

| Capability                          | Email | File Share | Screen | API |
|-------------------------------------|-------|------------|--------|-----|
| Invisible watermarking              | ✓     | ✓          | ✓      | ✓   |
| Visible watermarking                | ✓     | ✓          | ✓      | ✓   |
| Watermark attachments (PDF/image)   | ✓     | ✓          | —      | ✓   |
| Survives photos & printouts         | ✓     | ✓          | ✓      | ✓   |
| Survives re-typing on other devices | ✓     | —          | —      | —   |
| Analytics & viewership tracking     | —     | ✓          | —      | —   |
| Track forwards & replies            | ✓     | —          | —      | —   |

## DEPLOYMENT OPTIONS & INTEGRATIONS

- ⚙ Multi-tenant SaaS
- ⚙ Single-tenant SaaS
- ⚙ On-premises
- ⚙ Air-gapped environments
- ⚙ No client software required
- ⚙ SSO / identity integration
- ⚙ Microsoft Exchange integration
- ⚙ Google Workspace integration
- ⚙ Microsoft Purview integration
- ⚙ PoliteMail integration



### Contact Us

General Inquiries: [info@echomark.com](mailto:info@echomark.com)  
 Jeff Bednarczyk, Account Director: [jeff@echomark.com](mailto:jeff@echomark.com)  
 Zak Lewis, Account Director: [zak@echomark.com](mailto:zak@echomark.com)

Schedule  
a Demo



Product  
Videos

